Life Biosciences
Life Biosciences is a Boston-based biotech company developing gene therapies that aim to reverse aging in cells. Its lead therapy, ER-100, is in human trials for vision loss caused by glaucoma and other optic nerve diseases.
Analytics date: 05.11.2026
Basic information
Head office
75 Park Plaza, Level Three, Boston, MA 02116, USAHead officeGeography of business
United States of America- Singapore
Geography of businessDate of the last round
Last round 04/2026Date of the last roundTotal funds raised
$212M+Total funds raised
Analytics date: 05.11.2026
IPO Forecast
Life Biosciences remains privately held, and neither its management nor its co-founders have publicly discussed an IPO, a target exchange or a valuation. The company said its April 2026 Series D funds operations into the second half of 2027, covering completion of the ER-100 Phase 1 trial. Its next value milestones are clinical: in October 2026 it reported early safety data from the first three glaucoma patients and moved the trial to a higher dose, with results in the second indication, NAION, still to come. Life Biosciences has raised more than $238 million since its founding, based on company disclosures, and has not disclosed a valuation for any round.
Request price
Competitor Analysis
Comparison with other companies in the industry.
| Name | Valuation |
| Private companies | |
Isomorphic Labs | 000 |
Ultima Genomics | 0000 |
Colossal Biosciences | 00 |
Varda Space Industries | 0000 |
Mammoth Biosciences | 00 |
| Traded companies | |
Recursion Pharmaceuticals | 000 |
Schrödinger | 0000 |
Relay Therapeutics | 00000 |
Scribe Therapeutics | 00000 |
Metagenomi Therapeutics | 000 |